167 related articles for article (PubMed ID: 35538296)
1. The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients.
El-Khodary NM; Ghoneim AI; El-Tayaar AA; El-Touny EM
Cardiovasc Drugs Ther; 2023 Oct; 37(5):955-964. PubMed ID: 35538296
[TBL] [Abstract][Full Text] [Related]
2. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
[TBL] [Abstract][Full Text] [Related]
3. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
4. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway.
Liu X; Gai Y; Liu F; Gao W; Zhang Y; Xu M; Li Z
Cardiovasc Res; 2010 Oct; 88(1):150-8. PubMed ID: 20534773
[TBL] [Abstract][Full Text] [Related]
5. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study.
Chazov EI; Lepakchin VK; Zharova EA; Fitilev SB; Levin AM; Rumiantzeva EG; Fitileva TB
Am J Ther; 2005; 12(1):35-42. PubMed ID: 15662290
[TBL] [Abstract][Full Text] [Related]
6. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
7. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
El-Kady T; El-Sabban K; Gabaly M; Sabry A; Abdel-Hady S
Am J Cardiovasc Drugs; 2005; 5(4):271-8. PubMed ID: 15984909
[TBL] [Abstract][Full Text] [Related]
8. Effects of Trimetazidine on PDCD4/NF-κB/TNF-α Pathway in Coronary Microembolization.
Su Q; Li L; Zhao J; Sun Y; Yang H
Cell Physiol Biochem; 2017; 42(2):753-760. PubMed ID: 28683436
[TBL] [Abstract][Full Text] [Related]
9. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.
Sellier P; Broustet JP
Am J Cardiovasc Drugs; 2003; 3(5):361-9. PubMed ID: 14728070
[TBL] [Abstract][Full Text] [Related]
10. Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition.
Chen X; Xia X; Dong T; Lin Z; Du L; Zhou H
Drug Des Devel Ther; 2022; 16():2517-2527. PubMed ID: 35946039
[TBL] [Abstract][Full Text] [Related]
11. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
[TBL] [Abstract][Full Text] [Related]
12. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.
McClellan KJ; Plosker GL
Drugs; 1999 Jul; 58(1):143-57. PubMed ID: 10439934
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
[TBL] [Abstract][Full Text] [Related]
14. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up.
Xu X; Zhang W; Zhou Y; Zhao Y; Liu Y; Shi D; Zhou Z; Ma H; Wang Z; Yu M; Ma Q; Gao F; Shen H; Zhang J
Clin Drug Investig; 2014 Apr; 34(4):251-8. PubMed ID: 24470342
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials.
Marzilli M; Klein WW
Coron Artery Dis; 2003 Apr; 14(2):171-9. PubMed ID: 12655281
[TBL] [Abstract][Full Text] [Related]
16. Comparison between Glyceryl Trinitrate and Trimetazidine in Ischaemic Cardiomyopathy Patients.
Hoque MH; Kabir FI; Arzu J; Amin MR; Zaman SM; Ear-E-Mahabub SM; Joarder AI; Singha CK; Banerjee RS
Mymensingh Med J; 2019 Jan; 28(1):114-119. PubMed ID: 30755559
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.
Brottier L; Barat JL; Combe C; Boussens B; Bonnet J; Bricaud H
Eur Heart J; 1990 Mar; 11(3):207-12. PubMed ID: 2318223
[TBL] [Abstract][Full Text] [Related]
18. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris.
Shlyakhto EV; Almazov VV; Nifontov EM; Vakhrameyeva IV; Rudomanov OG; Zakharov DV; Kazarin VV; Vakhrameyeva NV
Am J Cardiovasc Drugs; 2002; 2(2):119-24. PubMed ID: 14727987
[TBL] [Abstract][Full Text] [Related]
19. The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischaemic ventricular dysfunction.
Feola M; Biggi A; Francini A; Leonardi G; Ribichini F; Ferrero V; Uslenghi E
Int J Cardiovasc Imaging; 2004 Aug; 20(4):315-20. PubMed ID: 15529915
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Ferrari R; Ford I; Fox K; Challeton JP; Correges A; Tendera M; Widimský P; Danchin N;
Lancet; 2020 Sep; 396(10254):830-838. PubMed ID: 32877651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
